MIZUHO MEDY CO.,LTD. (4595) Stock Price

Mizuho Medic operates primarily in the in vitro diagnostic medical device sector. The company conducts research and development independently and through industry-academia-government collaborations, engaging in planning, development, manufacturing, and sales based on ISO 13485 quality management standards. This approach enables the company to provide high-quality products that meet healthcare facility needs while delivering stable after-sales support.

Mizuho Medic's business is divided into two segments: "Hospital and Private Practice" and "OTC and Other." In the Hospital and Private Practice segment, the company manufactures and sells infectious disease immunological test kits and genetic test kits. Notably, rapid antigen test kits for influenza virus and COVID-19 have garnered significant attention.

In the OTC and Other segment, the company sells pregnancy test kits and ovulation test kits to general consumers. These products are available at pharmacies and drugstores nationwide and are used as part of self-medication initiatives. The company also provides fruit tree virus test kits for agricultural research facilities.

Mizuho Medic's flagship products include the "Quick Chaser" series of infectious disease immunological test kits. This series includes antigen detection kits for influenza virus and adenovirus, enabling rapid and simple testing. The company also offers the "Smart Gene" series of genetic test kits, which contribute to early diagnosis of infectious diseases.

The company distributes its products through domestic and international pharmaceutical wholesalers and distributors. This distribution network enables the company to supply products to a broad market and meet the needs of healthcare facilities and general consumers.

Mizuho Medic is pursuing technological innovation in the in vitro diagnostics field, guided by its management philosophy of "For People." The company aims to enhance corporate value by leveraging its vertically integrated operations based on ISO 13485 quality management standards to deliver high-quality products.

As part of its medium to long-term growth strategy, the company prioritizes revenue growth rate and operating profit margin on sales. In particular, it is expanding markets in the hospital and private practice sectors as well as the OTC and other segments, while advancing development of gene POCT devices and infectious disease POCT immunoassay products.

In the hospital and private practice sector, the company is developing gene POCT devices to create new markets. It is also expanding its product line of infectious disease POCT immunoassay products and advancing market development in the virus and bacteria fields.

In the OTC segment, the company is preparing to launch switched OTC products and expanding market share through partnerships with Alinamin Pharmaceutical. This initiative aims to increase penetration of products for general consumers.

Mizuho Medic is also considering entry into the environmental and food testing fields by applying its gene POCT testing technology. This diversification effort is intended to further enhance corporate value.

The company is also focusing on strengthening and developing its research and development personnel. Through recruitment of talented staff and educational initiatives, it aims to improve research and development capabilities and advance development of diagnostic items in new technologies and fields.

Expanding manufacturing capacity and streamlining production processes are also key priorities. The company is establishing stable supply systems through construction of new manufacturing facilities and installation of new production lines, thereby realizing stable supply of high-quality products.